Workiva Inc Stock News

Workiva Inc. delivered solid results in Q3 as revenue, client count, and the number of large contracts all grew in comparison to prior year. The new Pay vs Performance mandate will give Workiva and XB

Not all opportunities are created equal in a bear market.

Within the last quarter, Workiva (NYSE:WK) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 0 0 0

Workiva (NYSE:WK) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 0 0 0

Workiva (WK) delivered earnings and revenue surprises of 42.31% and 0.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Workiva Inc. (NYSE:WK ) Q3 2022 Results Conference Call November 2, 2022 5:00 PM ET Company Participants Mike Rost - Senior Vice President-Corporate Development and Investor Relations Marty Vanderploe

Upgrades SVB Leerink upgraded the previous rating for Moderna Inc (NASDAQ:MRNA) from Underperform to Market Perform. Moderna earned $5.24 in the second quarter, compared to $6.46 in the year-ago quart

Here are a couple of places investors might find growth in this difficult economic climate.

AMES, Iowa--(BUSINESS WIRE)--Workiva Inc. (NYSE:WK), the company powering transparent reporting for a better world, announced today that it plans to release its third quarter financial results on Wedn

Workiva (WK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Workiva (WK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The tria

U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session. Acumen Pharmaceuticals, Inc. (NAS

Upgrades For iQIYI Inc (NASDAQ:IQ), UBS upgraded the previous rating of Neutral to Buy. For the second quarter, iQIYI had an EPS of $0.01, compared to year-ago quarter EPS of $0.27. At the moment, the

The mean of analysts' price targets for Workiva (WK) points to a 25% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in